Core Insights - Humana Inc. is a health and well-being company with a market cap of $29.3 billion, providing various insurance services and clinical-care operations [1] Performance Overview - Humana's stock has underperformed the broader market, declining 13.1% over the past 52 weeks, while the S&P 500 Index gained 14.1%. Year-to-date, the stock is down 4.1%, compared to the S&P 500's 16.4% return [2] - The company has also lagged behind the iShares U.S. Healthcare ETF, which saw an 8.8% rise year-to-date [3] Earnings Report - On November 5, shares of Humana fell 6% following its Q3 earnings release, despite better-than-expected results. Adjusted revenue was $32.6 billion, and adjusted EPS was $3.24, both surpassing consensus estimates. The top line increased by 11.4% year-over-year, but the bottom line decreased by 22.1%, raising concerns about profitability [4] Analyst Expectations - For the current fiscal year ending in December, analysts project Humana's EPS to grow by 5.4% year-over-year to $17.08. The company's earnings surprise history is mixed, with three out of the last four quarters exceeding estimates [5] - Among 27 analysts covering the stock, the consensus rating is a "Moderate Buy," with seven "Strong Buy," two "Moderate Buy," 17 "Hold," and one "Strong Sell" rating [5] Price Target Adjustments - Truist Financial Corporation maintained a "Hold" rating on Humana but lowered its price target to $285, indicating a potential upside of 16.3% from current levels [6]